As members of the House expressed concerns with the number of clinical holds at Peter Marks’ Center for Biologics Evaluation and Research, Marks said at a conference on Wednesday that there is a way to manage the holds “that’s more user friendly,” noting CBER will work more in advance with sponsors.
Marks acknowledged an uptick in clinical holds for cell and gene therapies…